Soluble Thy-1 Polypeptide Inhibits Fibrosis via Integrin Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for progressive pulmonary fibrosis are inadequate, as they only decelerate tissue remodeling rather than halt or reverse it, and there is a lack of understanding of impaired tissue remodeling leading to fibrosis, characterized by persistent or aberrant fibroblast activation and excessive extracellular matrix deposition.
Innovation Solution
The use of a soluble Thy-1 polypeptide or its functional fragment, which targets αv integrins to inhibit profibrotic activation of fibroblasts and reverse tissue fibrosis by interfering with the integrin-dependent activation of latent TGF-β, thereby addressing the core molecular pathway regulating organ fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved medications are used to treat pulmonary fibrosis, then the progression of tissue remodeling is decelerated, but the fibrosis is not halted or reversed
Solution Approach 1:
The patent uses soluble Thy-1 as an intermediary molecule that binds to αv integrins on fibroblasts and myofibroblasts, blocking their interaction with latent TGF-β in the extracellular matrix. This mediator approach prevents TGF-β activation without requiring genetic modification or direct cellular intervention, thereby halting fibrotic tissue remodeling while maintaining treatment reliability
Solution Approach 2:
The invention extracts and isolates the Thy-1 protein domain that specifically binds to αv integrins, creating a soluble therapeutic agent that can be administered systemically. By extracting this specific functional domain from the full Thy-1 molecule, the treatment achieves targeted inhibition of fibrotic pathways while avoiding off-target effects, thus halting tissue remodeling progression
2Reliability
If fibroblasts are activated in response to fibrogenic stimuli, then tissue repair is initiated, but persistent activation leads to excessive extracellular matrix deposition and fibrosis
Solution Approach 1:
The soluble Thy-1 treatment is administered before excessive fibrosis develops, preemptively blocking αv integrin-mediated TGF-β activation. This preliminary intervention prevents the transition from beneficial fibroblast activation for tissue repair to harmful persistent activation and excessive matrix deposition, maintaining the balance between repair and fibrosis
Solution Approach 2:
The patent exploits the feedback loop where activated fibroblasts express αv integrins that further activate TGF-β, which in turn promotes more fibroblast activation. By introducing soluble Thy-1 that binds to αv integrins, this positive feedback loop is broken, allowing tissue repair to proceed without progressing to pathological fibrosis with excessive matrix deposition
3Reliability
If αv integrins are blocked to prevent TGF-β activation, then myofibroblast differentiation is inhibited, but the ability of fibroblasts to respond to physiological stimuli may be compromised
Solution Approach 1:
The soluble Thy-1 treatment selectively blocks αv integrin function specifically in the context of TGF-β activation and myofibroblast differentiation, while leaving other fibroblast functions intact. This localized inhibition approach prevents pathological fibrosis while preserving the adaptability of fibroblasts to respond to other physiological stimuli through alternative pathways
Solution Approach 2:
The patent uses partial blockade of αv integrin signaling rather than complete inhibition, achieving sufficient prevention of myofibroblast differentiation and TGF-β activation while allowing residual integrin function to maintain normal fibroblast adaptability and response to physiological stimuli. This partial action approach balances therapeutic efficacy with preservation of normal cellular functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The soluble Thy-1 polypeptide effectively treats and reverses tissue fibrosis by inhibiting myofibroblast differentiation and reducing fibrotic gene expression, promoting the resolution of established fibrosis and potentially halting its progression.
Implementation Method 1
Thy-1 contains an integrin-binding RGD-like motif (RLD) and regulates the phenotype of fibroblasts. Interactions of soluble Thy-1 with αvβ5 integrin inhibited lung fibroblast contraction-induced latent TGF-β1 activation and myofibroblast differentiation.
Implementation Method 2
Active TGF-β can be released from the latency-associated peptide following αv integrin binding and myofibroblast contraction. The soluble Thy-1 polypeptide interferes with the integrin-dependent activation of latent TGF-β.
Data Source
AI summary
The invention relates to a soluble Thy-1 polypeptide or a functional fragment thereof and pharmaceutical compositions including the soluble Thy-1 polypeptide or a functional fragment thereof. The invention also relates to the use of the soluble Thy-1 polypeptide or a functional fragment thereof for delivery to subjects with tissue fibrosis for treating, inhibiting, and/or reversing tissue fibrosis in the subject.